Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Influence of high-dose ketoconazole on the pharmacokinetics of docetaxel.

Cancer biology & therapy - 1 Jul 2006

Engels Frederike K, Mathot Ron A A, Loos Walter J, van Schaik Ron H N, Verweij Jaap

Abstract excerpt

OBJECTIVE: The pharmacokinetics (PK) of docetaxel are characterized by large inter-individual variability in systemic drug exposure (AUC) and drug clearance. The PK variability is thought to be largely related to differences in the catalytic function of CYP3A, involved in docetaxel metabolism and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents, Phytogenic
Share to Antineoplastic Combined Chemotherapy Protocols
Share to Cytochrome P-450 CYP3A

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cytochrome P-450 CYP3A Inhibitors

Share to Cytochrome P-450 Enzyme System

Share to Docetaxel

Share to Neoplasms

Share to Taxoids

Source

Identifiers

PMID: 16775418
DOI: 10.4161/cbt.5.7.2839

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-16775418-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Influence of high-dose ketoconazole on the pharmacokinetics of docetaxel.PMID 16775418Read ↗

Explaining interindividual variability of docetaxel pharmacokinetics and pharmacodynamics in Asians through phenotyping and genotyping strategies.Semantic proximity Read ↗

Pharmacokinetics and toxicity of docetaxel: Role of CYP3A, MDR1, and GST polymorphismsSemantic proximity Read ↗

Investigating the influence of relevant pharmacogenetic variants on the pharmacokinetics and pharmacodynamics of orally administered docetaxel combined with ritonavir.Semantic proximity Read ↗

Is Higher Docetaxel Clearance in Prostate Cancer Patients Explained by Higher CYP3A? An In Vivo Phenotyping Study with Midazolam.Semantic proximity Read ↗

Influence of garlic (Allium sativum) on the pharmacokinetics of docetaxel.Semantic proximity Read ↗

Influence of polymorphic OATP1B-type carriers on the disposition of docetaxel.Semantic proximity Read ↗

The effects of CYP3A4, CYP3A5, ABCB1, ABCC2, ABCG2 and SLCO1B3 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of docetaxel in nasopharyngeal carcinoma patients.Semantic proximity Read ↗

Pharmacogenetic screening of CYP3A and ABCB1 in relation to population pharmacokinetics of docetaxel.Semantic proximity Read ↗

Association between gene polymorphism and adverse effects in cancer patients receiving docetaxel treatment: a meta-analysis.Semantic proximity Read ↗

Pharmacogenetic pathway analysis of docetaxel elimination.Semantic proximity Read ↗

Life-Threatening Docetaxel Toxicity in a Patient With Reduced-Function CYP3A Variants: A Case ReportSemantic proximity Read ↗

Knockout of cytochrome P450 3A yields new mouse models for understanding xenobiotic metabolism.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.